Abstract:TPS616 Background: Women with high-risk HR+/HER2- breast cancer (BCA) receive additional chemotherapy to reduce disease recurrence. Preferred Taxane and Anthracycline based chemotherapy regimens have debilitating side effects such as cardiotoxicity, leukemia, peripheral neuropathy, severe fatigue, alopecia, downtime which are more common in black women thereby necessitating dose reductions. Metronomic cyclophosphamide, methotrexate, 5-fluourouracil (CMF) is an option but less preferred due to frequent dosing and longer therapy duration. Head-to-head comparison of CMF to anthracycline-based chemotherapy conducted 3 decades ago in early-stage BCA showed anthracycline benefit was driven by HER2+ disease with no benefit for HR+/HER2- BCA. Head-to-head comparison trials of CMF and Taxane-based regimen have not been conducted but single institution data suggest similar disease-free and similar overall survival but different toxicity profiles favoring CMF. In our ongoing trial, we converted all three chemotherapy drugs in CMF regimen to an all-oral regimen namely oral Cyclophosphamide, oral Methotrexate, oral Capecitabine (CMC) with the potential benefit of increased patient convenience, decreased costs (oral agents are generic; no chair time; no growth factors), and improved toxicity profile (low rates of grade III neutropenia, no port complications, no alopecia). This trial in progress aims to evaluate the feasibility of oral CMC by measuring the relative dose intensity in addition to the safety and tolerability of oral CMC. We hypothesize that 80% of patients will receive >85% of the intended dose of oral CMC. Methods: This is a Phase II, single arm, non-randomized study enrolling 25 patients with high-risk early-stage HR+ HER2- breast cancer to receive oral CMC regimen based on dose conversion equivalent bioavailability with conventional metronomic CMF chemotherapy. Enrolled patients will receive adjuvant therapy of oral cyclophosphamide 60 mg/m2 PO days 1-21 continuously, Methotrexate 15 mg/m2 PO Day 1, 8, and 15 and Capecitabine 650 mg/m2 PO BID Day 1- 14 to be given every 21 days for 8 cycles. The primary objective is to assess feasibility which is defined as 80% of patients (greater than 20 patients) maintaining a relative dose intensity (RDI) > 85%. The RDI is calculated as the ratio of the actual dose intensity/standard dose intensity; the average RDI for oral CMC regimen is the sum of RDI for each drug divided by 3. This study will be stopped if >25% of patients report Grade 4+ toxicity on oral CMC. The secondary objectives will assess quality of life as reported by the patients and report adverse effects. Clinical trial information: NCT06085742 . [Table: see text]

An All-Oral Combination of Metronomic Cyclophosphamide Plus Capecitabine in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: A Phase Ii Study

A Meta-Analysis of Combination Therapy Versus Single-Agent Therapy in Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: Results from Nine Randomized Phase III Trials

Capecitabine in combination with docetaxel in the treatment of anthracycline-resistant advanced breast carcinoma

Randomized Phase II Trial Comparing Docetaxel with or Without Low-Dose Metronomic Oral Cyclophosphamide in First-Line Treatment of Non-Triple-negative Advanced Breast Cancer.

Assessing the feasibility and cost-effectiveness of all oral adjuvant chemotherapy (cyclophosphamide, methotrexate, capecitabine) in high-risk hormone receptor positive breast cancer.

Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial

Whether Low-Dose Metronomic Oral Cyclophosphamide Improves the Response to Docetaxel in First-Line Treatment of Non-Triple-negative Metastatic Breast Cancer.

Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial

Phase Ii Study of Pseudomonas Aeruginosa-Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2-Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane

Safety and efficacy study of oral metronomic capecitabine in combination with pyrotinib for HER2-positive metastatic breast cancer: A phase II trial.

The effect of Gemcitabine combined Capecitabine regimens for anthracycline-and taxane-refractory metastatic breast cancer

Prospective Study of Cyclophosphamide, Thiotepa, Carboplatin Combined with Adoptive DC-CIK Followed by Metronomic Cyclophosphamide Therapy As Salvage Treatment for Triple Negative Metastatic Breast Cancers Patients (aged <45)

Metronomic Low-dose Oral Cyclophosphamide Plus Endocrine Therapy as Systemic Treatment for 23 Metastatic Breast Cancer Patients

Capecitabine Combined with Weekly Docetaxel in Chinese Patients > 65 Years with Anthracycline-Resistant Metastatic Breast Cancer.

Second-Line Combination Chemotherapy with Vinorelbine and Capecitabine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines and/or Taxanes

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer

UP-2.126: Low Dose Metronomic Oral Combined Administration of Etoposide and Cyclophosphamide in Metastatic Hormone Refractory Prostate Cancer After Docetaxol or Mitoxantrone Chemotherapy: A Phase II Study in China

Efficacy of Docetaxel Combined Capecitabine on Metastatic Breast Cancer

Metronomic chemotherapy using capecitabine and cyclophosphamide in metastatic breast cancer - efficacy, tolerability and quality of life results from the phase II METRO trial

Randomized Phase Iii Trial of Utidelone, A Genetically Engineered Epothilone Analog, in Combination with Capecitabine Versus Capecitabine Alone for Metastatic Breast Cancer Patients with Previous Taxane and Anthracycline Treatment.

Comparison Between Doublet Agents Versus Single Agent in Metastatic Breast Cancer Patients Previously Treated with an Anthracycline and a Taxane: a Meta-Analysis of Four Phase III Trials.